SMS Pharmaceuticals Limited has informed the Exchange about Investor Presentation

Date: 14th November, 2022

To, The Manager, Corporate Filings Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001

The Manager, Listing Compliance Department, National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here herewith a copy of investor presentation of the Company for the second Quarter and half year ended 30th September, 2022.

This Investor Presentation may also be accessed on the website of the Company at www.smspharma.com

Kindly take the same on record and disseminate on your website.

Thanking you Yours Faithfully

For SMS Pharmaceuticals Limited

Thirumalesh Tumma Company Secretary

SMS Pharmaceuticals Limited

Investor Presentation

November 2022

1

1

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by SMS Pharmaceuticals Limited (the “Company”), have been prepared solely for

information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in

connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing

detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty,

express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This

Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this

Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively

forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions

that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international

markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and

expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks,

as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this

Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by

third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

2

Table of Contents

Company Overview ………………………………………………………………………….04-13

Key Strategic Focus…….…………………………………………..………………..……...14-20

Financial Highlights ……………………………………………………………………….…21-25

Historical Performance at a Glance ………………………………………………….26-31

3

Company Overview

4

Company at a Glance

▪

▪

▪

▪

▪

▪

Genesis

A 30-years old research-driven company headquartered in Hyderabad.

focused company with 2 world class operating facilities in

API Hyderabad & Vizag, India.

Backward-integrated with low dependency on imports for material

raw

CRAMS Business

▪ Engaged in providing quality alternative manufacturing destination to multinationals for

their contract research and manufacturing needs.

▪ Installed Capacity: 1951 KL

▪ Top Customers: Mylan, Laurus, Pharmathen & Lupin

▪ Other Details: Huge manufacturing facility to support various range of APIs

Integrated model

80% of the intermediates are consumed by the API in-house business. Low import dependency.

JV with Spanish pharma giant Chemo Iberica S.A. for R&D

Vertically integrated through VKT Pharmaceuticals Pvt. Ltd. - An Associate company for semi-finished and finished formulations

Reach

▪

▪

▪

▪

▪

800+ Customers

75+ Countries

36+ Products

80 Regulatory Fillings

30 Process Patents

API Business

▪ ~96% of revenue is derived through API business

▪ 36+ products spread across 14 therapeutic segments.

▪ Top therapeutic segments - Anti-Ulcer, Anti-Migraine, ARV, Anti-Epileptic & Anti-

Erectile Dysfunction

▪ Global and Domestic leadership in key complex, specialized products like Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole , Eletriptan HBr, Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamuvidine, Lamotrigine , Efavirenz & Sitagliptin.

▪

Hyderabad Plant:

Capacity Overview

▪

▪

Installed Capacity: 120 KL

Products: Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole , Eletriptan HBr

▪

Visakhapatnam Plant:

▪ ▪

▪

Installed Capacity: 3,000 KL Products: Lamuvidine, Lamotrigine, Efavirenz & Sitagliptin. One of the largest single-block, single-product plant in Asia

Ranolazine,

Ibuprofen,

Tenofavir,

Levetiracetam,

▪

Certifications : USFDA, EUGMP, KFDA, CDCSO & PMDA

5

Transformation Over the Years

Diversification + Value-Addition + Expansion

Scaling Up

Became the largest manufacturer of Ranitidine API in the world

Acquisition

Acquired a facility to manufacture Niche and High value products to have a diversified portfolio.

Got Listed

SMS got listed on the NSE, BSE (Indian stock exchange) – Public Listed company.

Awards & Recognitions

Won the prestigious “Indian Pharma Bulk drug company of the year” award and “Best bulk drug export company of the year” award from Govt. of India

Way Forward

Successfully developed & commercialized Covid-19 treated APIs (Favipiravir & Remdesivir) in short time.

1989

1995

1997

2000

2003

2007

2010

2015

2017

2021

Inception

SMS Pharma was started with a single unit-product facility

Recognition

Recognized by govt. of India with a Jawaharlal Silver rolling trophy for the best productivity of the year.

USFDA Audit

Faced our first USFDA audit (successfully); SMS API was Part of a Para IV filing from an MCN company.

Green Field Project

Started a green field project to build an API facility in more than 100 acres of Land.

Demerger

Demerged SMS group into 2 Entities – SMS Pharmaceuticals, SMS Lifesciences.

6

Highly Competent Team…To Drive the Future Growth

Mr. Ramesh Babu Potluri Chairman & MD

Mr. P. Sarath Kumar Director

Sri Sarvepalli Srinivas Director

Sri Sravan Kudravalli Director

Mr. Vamsi Krishna Potluri Executive Director

• Post-graduate Technocrat. • Started his career in the year 1984 with Cheminor Drugs Limited (Group of Dr. Reddy’s Laboratory), Limited Hyderabad.

• Played a key role in getting for

approval

US FDA Ibuprofen

• With his innovative skills and methodological approaches in R & D he developed cost effective Ibuprofen by using cyanide route.

• Acquired

SMS Pharmaceuticals Limited in the became 1990 Managing Director of the Company.

and

• Founder

partner

of

the

• Holds a B.Com. Degree from

Sarath & Associates.

• Chartered Accountant with about 26 years of standing in the Profession of Chartered Accountancy and Consulting. Bachelor Law and of Certified Fraud Examiner & Certified Forensic Accounting Professional.

•

the University of Delhi.

• Accomplished

Business leader with 3+ decades of proven leadership experience in leading Public / Private Sector with enterprises decisive and forward thinking with a strong vision and strategic capability.

Bureau

Central

• Advisor to C.I.D. of AP Police and of Investigation in investigation of major Economic Offence cases and is a Member of Multi Disciplinary Investigation team.

/

• 32+ years of experience in leading Private Public Sectors)-National Handloom Development Corporation – Managing Ltd (NHDC) Textile Director – Corporation Ltd (NTC) Chairman Managing Director.

-National

&

•

• Commerce Graduate

from Osmania University and a Fellow member the Institute Chartered Accountants of India.

of

of

• Partner

a

in

of

reputed Chartered Accountancy firm and has experience in the Auditing, area Accountancy, Company Law matter, and Income Finance. Involved in handling Internal and of various Public and Private Companies Systems designing for clients.

Statutory

Audits

and

Tax

•

of

• Bachelor’s in Engineering in EEE from BITS Pilani Dubai Campus. in Engineering And Masters from Missouri Management & Science University Technology- Rolla. Joined Ohm Labs – the biggest manufacturing hub of Ranbaxy in US in the supply chain group and had hands on experience in managing the supply chain. • Eldest son of Mr. Ramesh Babu Potluri, Chairman and Managing Director, SMS Pharmaceuticals Ltd.

7

State-of-the-art Manufacturing Facilities

Particulars

Hyderabad

Visakhapatnam

Year of Establishment

2000

2010

Area (units in Sq. M)

Plant Area: 19,685 Built Up: 5,127

Plant Area: 3,45,007 Built Up: 39,704

Capacity

120KL

3,000 KL

Key Products

Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole, Eletriptan HBr etc.

Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamuvidine, Lamotrigine, Efavirenz, Sitagliptin etc.

Regulatory Approvals

USFDA,EUGMP, KFDA,CDSCO,PMDA USFDA,KFDA,CDSCO,PMDA

Key Features

• •

•

5 times approved by USFDA. Facility aligned for manufacturing niche small volume molecules. One of the largest exporter of Triptans

• •

•

•

•

3 times approved by USFDA. Flagship, Multipurpose API manufacturing facility. Facility aligned for manufacturing niche large-volume molecules. Huge CMO facility to cater highly reputed clients Dedicated Ibuprofen largest single -block, single product plant in Asia

Disclaimer: Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

8

Strong Thrust on R&D

Research & Development: Backbone of APIs

01

02

03

04

05

06

07

Product Development

▪ Added 20 new products to the company’s product basket over the past few years.

Technical Team ▪ Comprises 100+ scientists & 8 PHDs; 45 scientists ensure disciplined adherence to regulatory

standards and client specifications

Quality Management ▪ Optimized many Anti-Ulcer APIs to position the company as a leader in the respective

therapeutic area.

Equipped Technology ▪ Equipped with cutting edge technology & sophisticated equipment that has the capability to

support the entire R&D life cycle

DMFs & Patents

▪ Over 80+ DMFs filed; over 30 process patents filed

Scaling Up ▪ Product scale-up infrastructure comprises a kilo lab and a pilot plant. Pilot Plant is well equipped for DMF Filling. Kilo lab has a total capacity of scale up systems – 4,500 Ltrs

Innovation

▪ Developed an innovative path to recycle methyl mercaptan gas into useful solvent DMSO in Ranitidine with a goal of environment protection; received the Indo-US GCNC award for this successful achievement

9

Self-reliant Manufacturing Plants

➢ Pre-treatment plant capacity (MGF & Softner) 1750 Lts/ Hr.

▪ DM Water generation by RO & EDI - 1000 Lts / Hr. ▪ DM Water Storage capacity – 5000 Lts

➢ Power Generation by DG set 640 KV & 320 KV. Boilers 2Tons/Hr. & 3

Tons/Hr.

➢ Vacuum Pumps, Steam & Water jet ejectors & Nitrogen Plant 20 NM3/ Hr.

Particulars

Total No. of Reactors

Minimum Size

Maximum Size

Total Capacity

Glass Lined Reactors

SS Reactors

Hydro-generators

Distillation Still

Glass Flasks

SS Centrifuges

Rubber Lined Centrifuges

Dryers

No.

50

50 L

3,000 L

57 KL

17

31

2

1

5

18

1

16

10

…and a Wide Array of Manufacturing Capabilities

Equipment Name

Stainless steel Reactors Glass lined Reactors Leaf Filters Nutsch Filters Agitated Nutsche Filter Drier Sparkler Filter Centrifuges Rotary Cone Vacuum Drier Vacuum Tray Drier / Tray drier De-lumper Fluid Bed Drier Co-Mill Multi Mill Poly Gonal Blender Micronizer Micro Pulverizer Sifter Roller Compactor

MOC

SS MS-GL SS SS SS SS SS SS & MS GL SS SS SS SS SS SS SS SS SS SS

Capacity (Min-Max) 50 L – 32 KL 63 L – 10 KL 80 – 100 L 80 – 1500 L 2500 – 15000 L 10-177 L 24" - 60" 200 L – 3000 L 12 – 96 Trays 1000 – 2000 Kg/Hr 300 – 500 Kg 500 – 750 Kg/Hr 50-300 Kg/Hr 150 L – 3 KL 20 – 200 Kg/Hr 50-250 Kg/Hr 100-500 Kg/Hr 400 Kg/Hr

Note: SS – Stainless Steel , MS GL – Mild Steel Glass Lined

11

Supported by Comprehensive Chemicals and Process Capabilities…

Distillation (Normal & Vaccum)

Distillation (Normal & Vaccum)

Condensation

Oxidation

Fridel Craft

Mesylation

Silyation

Bromination

n o i t a r t i N

n o i t a r d y h e D

Oxidations & Reductions

Cyclisation

Methylation

Reduction

Condensation

Epoxidation

Electrophillic aromatic substitutions Ketone Reductions

Salt Formation

Grignard Reaction

n o i t a l y k l A

Salt Formations

Hydro-Carbon Reactions

Alkylation

Dechlorination

Suzuki Coupling Reactions

n o i t a n i r o h C

l

s i s y l o r d y H

n o i t a l y c A

Coupling Reaction

Hydrogenation

Acid Chloride reaction

▪ Minimum temperature as -105°C and maximum temperature as 170°C in the reactor while manufacturing of various

products in our manufacturing plant.

▪ Capable to handle the above-mentioned reactions for various Active pharmaceutical ingredients of different therapeutic

categories to human consumption manufactured on site.

12 12

…Resulting into Long Lasting Relationships with Marquee Clients

13

Certifications

14

CSR Activities

✓ Society Service

✓ Educational Infrastructure

✓ Empowering Differently Abled Children

15

CSR Activities

✓ Sponsored & Constructed Z.P. High School at Poosapatriga Village, Andhra Pradesh

✓ Sponsored for Borewell drilling Chinthapalli Village, Andhra Pradesh

✓ Donation of Oxygen cylinders at Kopperla

Village in aid of Covid 19 victims

16

CSR Activities

✓ Sponsored & Constructed R.O water plant at Thammayapalem

Viliage, Andhra Pradesh

✓ We also Donated INR 20 Lakh to the police force to support their selfless service during covid times.

✓ Extended financial support to Campus

challenge

17

Awards/Accolades

Indo US NCGC Award

❑ First Indian pharma company to receive Indo-US GCNC award for adopting green chemistry practices

Pandit Jawaharlal Nehru Silver Rolling Trophy

❑ Awarded Pandit Jawaharlal Nehru Silver Rolling Trophy for the best productivity effort in Andhra Pradesh

Bulk Drug Company of the Year

❑ India Pharma Bulk Drug Export Company of the Year Award from Government of India.

❑ Received the Indian Pharma Bulk Drug Company

of the Year Award

18

Key Strategies

19

Key Strategic Focus

Niche Product Portfolio Carved out a strong presence in complex, niche API therapies with a global leadership in multiple products

Expansion

Brownfield capex of Rs. 200 crores in FY21 to augment leg of growth

the next

Unique Value Proposition domain Global expertise, long- standing relationships, Economies of scale

Strong leadership,

presence, cost

Diversification

Portfolio of 36+ products across 10+ therapies catering 75+ countries in regulated and semi-regulated markets

De-risked and Integrated Value Chain Backward and Vertical Integration provides cost synergies and growth opportunities. Strategic focus on backward integration and intermediates has reduced supply chain and forex risks significantly. (~10%-15% of the imports from China)

20

Niche Product Portfolio

Leadership in Select High-Value, Complex APIs

API portfolio comprises of specialized and profitable products in niche therapeutic areas. Reflects the strong ability to foray into other high-value, niche and complex products

Currently developing multiple products every year across 10+ therapeutic areas, which include High Value as well as High Volume Products

SMS Pharma has demonstrated an ability in the past to foray into new complex, profitable products and currently enjoys leadership position in multiple API molecules.

The company has presence in multiple margin-lucrative, non- commoditized therapeutic areas like ARV, Anti-Epileptic, Anti- Migraine, Anti-Anginal, etc.

The company has an expertise in synthesis and R&D which can be leveraged to foray into complex API products and therapies

The company enjoys global products across therapies.

leadership position across 10+

Growing share of High Value Products

By Value (%)

20%

40%

7%

14%

ARV Anti-Epileptic Anti-Migraine Other

4%

8%

7%

Anti-Ulcer Anti-Aginal Anti-Inflammatory

By Volume (%)

36%

28%

28%

2%

4%

1%

1%

ARV

Anti-Ulcer

Anti-Epileptic

Anti-Aginal

Anti-Migraine

Anti-inflammatory

Other

Note: As of FY22

21

Expansion

With ~ Rs. 200 crores capex at Vishakhapatnam Facility in FY21, the company is fully geared up for the next level of growth.

•

•

The brownfield capex is aimed towards capacity augmentation of multiple products and therapies.

The incremental capacity addition through the capex is 1,300 KL, predominantly aimed towards Ibuprofen capacity expansion.

• With this capex, company is expected to be one of the largest Ibuprofen manufacturers

globally.

•

The company is also leveraging long-standing relationships, domain expertise and strong R&D knowledge to foray into new therapies, products and geographies

• Majority of the capex is funded through internal accruals and minimal debt, thus

maintaining the robust Balance Sheet position.

• Higher margins and profitability ratios expected through operating leverage and

incremental revenue.

22

Unique Value Proposition

Global Presence ~80% Exports Revenue (including deemed exports) in 75+ countries across 5 continents – Lower dependency on single country/region

Strong Domain Expertise Promoters and Senior Management with a strong business pedigree and domain expertise in APIs and Intermediates – internal Alignment of stakeholders

interest of all

Cost Leadership From procurement to production till sales have a strong foundation and sound setup. Backward cost- efficient Higher Profitability

integration manufacturing

ensures –

Long-standing Relationships

standing

relationships

Long with suppliers and customers - Cost-efficient, consistent, sustainable raw material supply and revenue

Economies of Scale Leadership position in key products, coupled with integration provides economies of scale – Lower Competitive Intensity & Higher Margins

backward

23

Diversification

Well-diversified across Geographies, Markets, Therapies, Products and Customers = Risk Reduction and Multiple Growth Avenues

01

02

03

04

Geography

Markets

API Therapies

Customers

• Domestic - Export mix at

19%:81% for FY22

• Presence across 75+

countries

• None of the region

contributes more than 2/3rd of the revenue with Africa contributing the highest at ~39.0% of total sales

• Regulated Markets contributed ~36% of sales in FY22, with USA being the highest at ~23%

• Semi- Regulated Markets

contributed ~45% of sales in FY22, with Africa being the highest at ~39%

• Domestic Markets contributed

~19% of sales in FY22, with Cipla being the highest at ~4%.

• Top 5 therapies contributed

~76% of sales in FY22

• ARV products contributed

highest at 39% to sales in FY22

• Top 10 products contributed to

84% to sales in FY22

• Leaders in Domestic market in

most of top 10 products

• Domestic: Largest client contributes ~19% of domestic sales whereas top 10 clients contribute ~84% in FY22.

• Exports: Largest client contributes ~25% of exports sales whereas top 10 clients contribute ~58% in FY22.

24

De-risked & Integrated Value Chain

Backward Integration

➢ Over the years, SMS Pharma has strategically invested in backward integration to be self-reliant and reduce supply chain risk.

• 80% of the intermediates are

consumed by the API in-house business.

• Low dependency on China for raw material sourcing (~10% of the raw material sourced from China)

Strategic Investments across the Value Chain

Verticle Integration

➢ Vertically integrated through VKT

Pharmaceuticals Pvt. Ltd. - An Associate company

• VKT Pharma Private Limited is engaged in formulations & semi-

manufacture of finished formulations viz. pellets.

• Company holds 42.6% as on 31st March 2022 in VKT Pharma and balance is held by promoters which give the entire control in the manufacturing cycle.

• VKT Pharma has gives an edge by saving costs & eliminating imports with respect to formulations.

• VKT has 6 approved ANDA’s out of which

4 received in January 2022.

25

Financial Highlights

26

Consolidated Revenue Break-up – Quarterly

Q1FY21 Q2FY22 Q1FY21

Q1FY23

Q2FY23 Q1FY22

e s i w

- t n e m g e S

e s i w - y h p a r g o e G

99.6%

99%

0.4%

1%

99.8%

0.2%

API

Intermediates & Others

API

Intermediates & Others

API

Intermediates & Others

Q1FY21 Q2FY22 Q1FY21

92%

8%

Q1FY23

82%

18%

Q2FY23 Q1FY22

80%

20%

Domestic

Exports

Domestic

Exports

Domestic

Exports

27

Consolidated Revenue Break-up – Half-Yearly

e s i w

- t n e m g e S

e s i w - y h p a r g o e G

Q1FY21 H1FY22 Q1FY21

H1FY23

96%

4%

99.7%

0.3%

API

Intermediates & Others

API

Intermediates & Others

Q1FY21 H1FY22 Q1FY21

41%

25%

34%

Domestic Exports Deemed Exports (EOU & SEZ)

H1FY23

65%

4%

31%

Domestic Exports Deemed Exports (EOU & SEZ)

28

API Therapy-wise Revenue Break-up – Quarterly

Q1FY21 Q2FY22 Q1FY21

Q1FY23

Q2FY23 Q1FY22

10% 5%

14%

10%

6%

55%

ARV

Anti-Ulcer

5% 10%

29%

27%

2%

11%

16%

58%

13%

3%

11%

3%4%

8%

ARV

Anti-Ulcer

ARV

Anti-Ulcer

Anti-Erectile dysfunction

Anti-Erectile dysfunction

Anti-Migraine

Anti-Erectile dysfunction

Anti-Migraine

Anti-Migraine

Anti-Epileptic

Others

Anti-Epileptic

Anti_Diabetic

Anti-Epileptic

Anti_Diabetic

Others

Others

29

API Therapy-wise Revenue Break-up – Half-Yearly

H1FY22

H1FY23

9% 10%

44%

12%

5%

7%

57%

ARV

Anti-Ulcer

Anti-Epileptic

Anti-Migraine

Anti-Erectile Dysfunction

Others

17%

6%

8%

16%

5%4%

ARV Anti-Ulcer Anti-Epileptic Anti-Migraine Anti-Erectile Dysfunction Anti-Diabetic Others

30

Consolidated Profit & Loss Statement

Particulars (Rs. Crores)

Net Revenue from Operations

Other Income

Total Revenue

COGS

Gross Profit

Gross Margin (%)

Employee Expenses

Other Expenses

EBITDA

EBITDA Margin (%)

Finance Costs

Depreciation

PBT Taxes Reported PAT

Add: Share of Associate Profit / (Loss)

PAT After MI & Assoc.

PAT Margin

EPS

Q2 FY23

Q1FY23

YoY%

-9%

H1 FY23

H1FY22

223.8

337.7

YoY%

-34%

159.4

0.6

160.0

115.9

44.1

27.7%

13.1

16.9

14.2

8.9%

5.2

8.1

0.8 0.1 0.7 -2.7

-2.0

0.5%

-0.24

QoQ%

148%

51%

Q2FY22

174.7

1.4

176.1

95.1

81.0

64.4

0.8

65.2

36.0

29.2

-46%

45.3%

-1,767 bps

46.4%

-1,870 bps

12.6

16.6

-0.0

0.0%

4.9

7.9

-12.8 -2.6 -10.2 -2.6

-12.8

-15.8%

-1.51

12.1

20.8

48.2

-

-71%

890 bps

27.6%

-1,868 bps

4.8

8.1

35.3 10.2 25.0 -2.0

23.0

14.3%

2.72

-

-

-

-

-

-

-

-

-

-

1.4

225.2

152.0

73.3

32.7%

25.7

33.4

14.2

6.3%

10.1

16.0

-12.0 -2.5 -9.5 -5.3

-14.8

-4.2%

-1.75

2.6

340.3

181.0

159.4

47.2%

24.0

41.5

93.9

-54%

-1,446 bps

-85%

27.8%

-2,147 bps

9.8

16.1

68.0 19.8 48.2 -1.6

46.6

14.3%

5.50

-

-

-

-

-

31

Consolidated Balance Sheet

Equities & Liabilities (Rs. crores)

Sept-22

Mar-22

Equity

Equity Share capital

Other Equity

Non Controlling Interest

Total Equity

Financial liabilities

(i) Borrowings

(ii) Other Financial liabilities

Other non current Liability

Deferred tax liabilities (Net)

Provisions

Total Non Current Liabilities

Financial liabilities

(i) Borrowings

(ii) Trade Payables

(iii) Other financial liabilities

Provisions

Other current liabilities

Current tax liabilities (Net)

Total Current Liabilities

8.5

444.6

-

453.0

8.5

461.8

-

470.3

132.4

149.5

1.1

-

37.1

1.5

172.0

119.4

0.8

99.2

10.0

1.1

2.4

-

2.1

-

39.6

1.6

192.7

110.6

1.0

72.9

6.8

1.0

4.2

-

232.9

196.5

Assets (Rs. crores)

Non Current assets

Property, Plant and Equipment

Capital work in progress

Intangible assets

Right to use assets

Financial Assets

(i) Investments

(ii) Other Financial Assets

Deferred Tax Assets (net)

Other non-current assets

Total Non Current Assets

Current Assets

Inventories

Financial Assets

Investments

(i) Trade receivables

(ii) Cash and Bank Balances

(iii) Bank Balances & Financial Assets

Current Tax Assets(Net)

Other current assets

Total Current Assets

Sept-22

Mar-22

422.2

17.4

1.6

1.4

15.8

7.7

-

4.6

470.7

261.6

-

93.7

0.5

0.2

9.2

22.2

387.2

434.1

11.0

1.4

2.6

21.5

7.6

-

4.3

482.5

251.1

-

48.5

46.6

0.4

4.5

26.1

377.1

Total Equity and Liabilities

857.9

859.5

Total Assets

857.9

859.5

32

Consolidated Cashflow Statement

Particulars (Rs. crores)

Sept-22

Sept-21

Net Profit before Tax and Extraordinary items

Adjustments for: Non Cash Items / Other Investment or Financial Items

Operating profit before working capital changes

Changes in working capital

Cash generated from Operations

Direct taxes paid (net of refund)

Net Cash from Operating Activities

Net Cash from Investing Activities

Net Cash from Financing Activities

Net Decrease in Cash and Cash equivalents

Add: Cash & Cash equivalents at the beginning of the period

Cash & Cash equivalents at the end of the period

-12.0

26.1

14.1

-28.8

-14.7

-4.5

-19.2

-8.6

-18.3

-46.1

46.6

0.5

68.3

23.7

91.9

-51.5

40.5

-14.5

26.0

-19.0

-17.4

-10.4

40.4

30.0

33

Historical Performance at a Glance

34

Strong Financial Performance

Revenue (Rs. Crores)

EBITDA (Rs. Crores)

PAT (Rs. Crores)

Consolidat ed

463

465

+3%

412

563

520

93

90

+6%

80

125

120

+18%

63

62

40

32

32

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

EBITDA Margin (%)

PAT Margin (%)

+480bps

20.2%

19.4%

19.4%

22.1%

23.0%

+616bps

10.8%

13.1%

8.6%

7.7%

6.9%

35

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

35

Strong Financial Performance

EPS (In Rs)

Net Worth (In Crores)

Leverage (X)

Consolidat ed

+18%

7.4

7.4

4.7

3.8

3.7

322

285

494

428

+15%

348

0.48

0.42

0.41

0.58

0.53

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

ROCE (in %)

ROE (in %)

22.8%

21.0%

19.4%

14.8%

11.9%

13.4%

12.2%

14.2%

13.8%

8.9%

36

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

36

Consolidated Profit & Loss Statement

Particulars (Rs. crores)

Net Revenue from Operations

Other Income

COGS

Gross Profit

Gross Margin (%)

Employee Expenses

Other Expenses

EBITDA

EBITDA Margin (%)

Finance Costs

Depreciation

PBT before exceptional item

Exceptional Expense/(Gain)1

Share in Profit/(loss) in JV and Associates

PBT

Taxes

Reported PAT

Cash PAT

PAT Margin1 (%)

Earnings Per Share2 (EPS)

FY22

519.9

5.2

275.5

249.6

48.0%

51.0

79.1

119.5

23.0%

18.9

32.2

68.5

0.0

-5.7

62.8

0.6

62.2

94.4

13.1%

7.35

FY21

563.2

3.5

340.0

226.6

40.2%

41.2

60.9

124.6

22.1%

11.2

22.3

91.1

0.0

1.6

92.7

30.2

62.5

84.8

11.1%

7.39

FY20

411.9

5.1

280.0

131.9

32.0%

39.4

12.7

79.9

FY19

464.9

3.4

327.6

137.4

29.5%

35.6

11.7

90.1

FY18

462.7

2.4

324.4

138.3

29.9%

32.8

12.1

93.3

19.4%

19.4%

20.2%

12.2

22.1

50.7

0.0

-1.1

49.6

18.1

31.6

53.6

7.7%

3.73

11.9

19.3

62.3

0.0

-1.4

60.9

20.9

40.0

59.3

8.6%

4.70

15.5

19.9

60.3

0.0

-8.7

51.6

19.9

31.7

51.6

6.9%

3.80

37

Consolidated Balance Sheet

Equities & Liabilities (Rs. crores)

FY22

FY21

FY20

FY19

FY18

Assets (Rs. crores)

FY22

FY21

FY20

FY19

FY18

Equity

Equity Share capital

Other Equity

Non Controlling Interest

Total Equity

Financial liabilities

(i) Borrowings

(ii) Other Financial liabilities

Other non current Liability

Deferred tax liabilities (Net)

Provisions

8.5

485.3

0.0

493.8

8.5

419.7

0.0

428.2

149.5

147.4

2.1

0.0

39.6

1.8

3.2

0.0

53.9

1.8

8.5

339.8

0.0

348.2

68.2

4.8

0.0

39.7

1.7

Total Non Current Liabilities

192.9

206.3

114.5

Financial liabilities

(i) Borrowings

(ii) Lease Liabilities

(iii) Trade Payables

(iii) Other financial liabilities

Provisions

Other current liabilities

Current tax liabilities (Net)

Total Current Liabilities

110.6

103.1

1.0

72.9

6.8

0.8

4.2

0.0

0.9

65.4

17.0

0.8

8.2

0.0

61.2

0.0

44.5

28.4

0.7

10.4

0.0

8.5

313.5

0.0

321.9

8.5

276.0

0.0

284.5

62.2

0.0

0.0

30.6

1.5

94.3

70.8

0.0

47.7

13.0

0.7

10.4

0.0

71.4

0.0

0.0

23.0

2.2

96.6

58.4

0.0

38.7

17.5

0.7

5.9

0.0

Non Current assets

Property, Plant and Equipment

Capital work in progress

Intangible assets

Right to use assets

Financial Assets

(i) Investments

(ii) Other Financial Assets

Deferred Tax Assets (net)

Other non-current assets

Total Non Current Assets

Current Assets

Inventories

Financial Assets

Investments

(i) Trade receivables

(ii) Cash and Bank Balances

(iii) Bank Balances & Financial Assets

Current Tax Assets(Net)

Other current assets

Total Equity and Liabilities

883.0

829.9

607.9

558.8

502.5

Total Assets

196.3

195.4

145.2

142.5

121.5

Total Current Assets

Non current Asset held for sale

434.1

11.0

1.4

2.6

0.0

452.3

6.7

1.6

3.6

0.0

45.0

45.0

7.6

0.0

4.3

5.8

0.0

5.6

505.9

502.9

275.2

42.1

0.8

4.5

0.0

25.8

5.6

0.0

35.1

389.1

280.1

18.3

1.1

0.0

0.0

27.0

5.6

0.0

19.1

351.2

278.9

8.2

0.4

0.0

0.0

28.4

4.4

0.0

13.8

334.0

251.1

137.8

129.2

136.4

107.5

0.0

0.0

48.5

46.5

0.4

4.5

26.1

377.1

0.0

883.0

0.0

0.0

105.7

40.4

0.4

3.0

22.0

309.3

0.0

0.0

0.0

48.8

9.5

0.4

3.1

27.8

218.8

0

0.0

0.0

26.0

14.8

0.3

0.4

29.6

207.6

0.0

0.0

0.0

24.1

12.6

0.6

0.0

23.6

168.5

0.0

812.2

607.9

558.8

502.5

38

Consolidated Cashflow Statement

Particulars (Rs. crores)

Net Profit before Tax and Extraordinary items

Adjustments for: Non Cash Items / Other Investment or Financial Items

Operating profit before working capital changes

Changes in working capital

Cash generated from Operations

Direct taxes paid (net of refund)

Net Cash from Operating Activities

Net Cash from Investing Activities

Net Cash from Financing Activities

Net Decrease in Cash and Cash equivalents

Add: Cash & Cash equivalents at the beginning of the period

Cash & Cash equivalents at the end of the period

FY22

68.7

45.8

114.4

-59.3

55.1

-14.9

40.2

-27.2

-6.9

6.2

40.4

46.6

FY21

91.1

27.8

118.9

-12.4

106.5

16.0

90.5

-151.6

92.0

30.9

9.5

40.4

FY20

50.8

28.7

79.4

-27.6

51.8

12.1

39.7

-42.6

-2.4

-5.3

14.8

9.5

FY19

62.4

26.8

89.2

-26.0

63.1

13.4

49.8

-34.7

-12.9

2.2

12.6

14.8

FY18

60.3

31.1

91.4

-48.5

43.0

11.1

31.8

-16.6

-14.9

0.3

12.3

12.6

39

For further information, please contact

Company:

Investor Relations Advisor:

CIN: L24239TG1987PLC008066

CIN: U74140MH2010PTC204285

Mr. Thirumalesh Tumma Email: complianceofficer@smspharma.com Contact no.: +91 9100123244

Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar E: jigar.kavaiya@sgapl.net / chinmay.m@sgapl.net T: +91 9920602034 / +91 9860088296

www.smspharma.com

www.sgapl.net

40

40